Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: khrnyc who wrote (1898)	1/21/1998 2:01:00 PM
From: Tokyo VD	Respond to of 7041

Hmmm... This is not exactly right. While Pfizer did use the IIEF questionnaire for a few of its many trials on sildenafil, it wasn't the sole endpoint for the majority of its trials. In fact, if you had done a little homework, you would have read that Pfizer conducted some of its studies on animal models and men suffering from spinal cord injury (using Rigiscan testing for both models--some of the animals refused to answer the IIEF questions). This is why Pfizer is a real company on the doorstep of FDA approval. Now, it is a different story if you are arguing that you believe Zonagen's trial results with the IIEF endpoint are comparable to Pfizer's trial results with IIEF endpoint.

To: khrnyc who wrote (1898)	1/21/1998 2:10:00 PM
From: Tokyo VD	Read Replies (1) \| Respond to of 7041

So, if you look at the two Phase III studies, you got numbers that were statistically significant. These "efficacy" rates for a subset of the IIEF (erectile function domain) for a 40 mg dose of phentolamine po were 40% versus 17% on placebo (parallel design) and 34% versus 21% placebo (crossover). Pfizer's reported outcomes from study with IIEF endpoints (subset GAQ) was as follows: Placebo 27.7%, 5mg 47.7%, 25mg 60.9%, 50mg 72.9%, and 100mg 77.8%. I'm not sure why you still feel compelled to argue your investment in this company (which is now down almost ten percent from when you signed on). Tokyo